PULMONARY EMBOLISM
Condition Identity
Pulmonary Embolism
Acute thromboembolic emergency
Massive (high-risk) vs Sub-massive (intermediate-risk) vs Low-risk PE
Part of venous thromboembolism (VTE) spectrum along with deep vein thrombosis (DVT)
Epidemiology
Risk Factors
- Prolonged immobility (long-haul travel, bed rest, hospitalisation)
- Recent surgery (especially orthopaedic, abdominal, pelvic)
- Active malignancy
- Prior VTE
- Inherited thrombophilia (Factor V Leiden, Prothrombin G20210A, Protein C/S deficiency, Antithrombin deficiency)
- Antiphospholipid syndrome
- Pregnancy and the puerperium (6 weeks postpartum highest risk)
- Combined oral contraceptive pill or hormone replacement therapy
- Obesity (BMI >30 kg/mยฒ)
- Acute medical illness (sepsis, MI, stroke, heart failure)
- Central venous catheter
- Nephrotic syndrome
- Chronic inflammatory conditions (IBD, SLE)
- Dehydration
Signs & Symptoms
- Tachycardia (most common sign; HR >100 bpm)
- Tachypnoea (RR >20 breaths/min)
- Hypoxia (SpOโ <94% on room air)
- Hypotension (systolic <90 mmHg: massive PE)
- Raised JVP (right heart failure)
- Right ventricular heave
- Loud P2 (pulmonary component of second heart sound)
- Tricuspid regurgitation murmur (acute cor pulmonale)
- Unilateral leg swelling, tenderness, warmth (DVT signs)
- Pleural rub (pulmonary infarction)
- Low-grade fever
- Dyspnoea (most common; sudden onset)
- Pleuritic chest pain (sharp, worse on inspiration; suggests peripheral/smaller PE)
- Haemoptysis (blood-stained sputum)
- Cough (usually dry)
- Syncope or presyncope (large PE with haemodynamic compromise)
- Palpitations
- Leg pain, swelling, redness (DVT symptoms in 50% of cases)
- Anxiety and sense of impending doom
Complications
DOWNSTREAM CLINICAL COMPLICATIONS & SEQUELAE
- Haemodynamic collapse and cardiac arrest (massive PE)
- Right ventricular failure and acute cor pulmonale
- Pulmonary infarction and infarction pneumonia
- Chronic thromboembolic pulmonary hypertension (CTEPH)
- Paradoxical embolism via patent foramen ovale (PFO)
- Post-thrombotic syndrome (from DVT component)
- Recurrent VTE (especially if unprovoked)
- Death
Diagnostic Criteria
DIAGNOSTIC RED FLAGS & EMERGENCY RULE-OUTS
- Haemodynamic instability (massive PE): immediate systemic thrombolysis or surgical embolectomy
- SpOโ <90% not responding to supplemental oxygen
- Syncope with persistently low BP
- Bilateral saddle embolism on CTPA
- RV strain: new RBBB, S1Q3T3 pattern on ECG
- Troponin or BNP elevation (intermediate-high risk PE)
- Clinical probability assessment before imaging is essential
- Wells Score for PE: 1 point each for DVT symptoms, HR>100, prior PE/DVT, haemoptysis, malignancy; 3 points each for PE more likely than alternative, immobilisation/surgery in past 4 weeks
- Geneva Score: alternative validated clinical tool
| Condition | Distinguishing Features | Recommended Workup |
|---|---|---|
| Acute MI or ACS | โ | โ |
| Pneumonia โ | โ | โ |
| Pneumothorax โ | โ | โ |
| Aortic dissection โ | โ | โ |
| Pericarditis or cardiac tamponade | โ | โ |
| Pleuritis | โ | โ |
| Musculoskeletal chest pain | โ | โ |
| Anxiety or panic attack | โ | โ |
Investigations
Bedside Tests
- Oxygen saturation and arterial blood gas
- 12-lead ECG (sinus tachycardia most common; S1Q3T3; new RBBB)
- Echocardiography (RV dilatation, septal flattening, McConnell sign)
- Compression ultrasound of lower limbs (DVT)
First-Line Diagnostic Tests
- D-dimer (high sensitivity; only use in low/intermediate clinical probability)
- High-sensitivity troponin (RV injury marker)
- BNP or NT-proBNP (RV strain marker)
- Full blood count
- Urea and electrolytes
- Coagulation screen
- Blood cultures if septic cause considered
- Chest X-ray (usually normal or non-specific; Hampton hump, Westermark sign โ rare)
Confirmatory & Specialized Tests
- CT pulmonary angiography (CTPA): investigation of choice; >95% sensitivity
- V/Q scan: alternative if CTPA contraindicated (pregnancy, renal impairment, contrast allergy)
- Formal lower limb venous Doppler ultrasound
- Pulmonary angiography: gold standard (rarely used)
- Cardiac MRI: used in research/specialist centres
Continuous & Serial Monitoring
- Continuous cardiac monitoring
- Oxygen saturation monitoring
- Blood pressure and urine output
- Serial troponin and BNP if intermediate-risk
- Anti-Xa levels if LMWH in renal impairment or pregnancy
Nonpharmacological Management
- Supplemental oxygen to maintain SpOโ >94% (88โ92% if at risk of hypercapnia)
- IV access and fluid resuscitation (cautiously in massive PE โ excessive fluid may worsen RV failure)
- Rest during acute phase; graduated mobilisation with compression stockings
- Graduated elastic compression stockings (20โ30 mmHg) to prevent post-thrombotic syndrome
- Avoid prolonged immobility
- Haemodynamic monitoring: arterial line and central venous pressure in massive PE
Monitoring
- Haemodynamic stability within 24โ48 hours
- SpOโ >94% on decreasing supplemental oxygen
- Improvement in RV function on echocardiography
- Falling troponin and BNP
- No recurrent symptoms of PE or DVT
- INR daily during warfarin initiation (target 2โ3)
- Anti-Xa levels in pregnancy, renal impairment, extremes of weight
- Renal and hepatic function before and 1 month after DOAC initiation
- Full blood count (bleeding surveillance)
- Clinical review at 1 and 3 months post-discharge
- Repeat echocardiography at 3 months to exclude CTEPH if symptoms persist
- Thrombophilia screen at 3 months (after anticoagulation withdrawn)
- Duration of anticoagulation: 3 months (provoked); โฅ6 months (unprovoked); lifelong (cancer, antiphospholipid syndrome, recurrent PE)
- Haemodynamic deterioration despite anticoagulation
- Recurrent PE confirmed on imaging
- Major bleeding on anticoagulant therapy
- CTEPH confirmed: refer to specialist pulmonary hypertension centre
- Most clot burden resolves over 3โ6 months with anticoagulation
- RV function normalises in the majority within 4โ6 weeks
- Dyspnoea may persist for weeks to months
Prevention
- Pharmacological VTE prophylaxis in all hospitalised medical and surgical patients
- LMWH or fondaparinux prophylaxis post-surgery
- Early mobilisation after surgery
- Graduated compression stockings in high-risk surgical patients
- Avoid oestrogen-containing contraceptives in high-risk women; consider progestogen-only or non-hormonal methods
- Avoid prolonged immobility
- Adequate hydration
- Regular exercise
- Graduated compression stockings for travellers at risk
- Anticoagulant medication adherence
- Signs of bleeding (bruising, prolonged bleeding, black stools, haematuria)
- When to seek urgent review (chest pain, breathlessness, leg swelling)
- Avoiding NSAIDs and aspirin while on anticoagulants (increased bleeding risk)
- VTE prevention during future travel or hospitalisation
EMERGENCY RETURN PRECAUTIONS
- Sudden worsening dyspnoea or chest pain
- Haemoptysis
- Unexplained tachycardia or hypotension
- Signs of major bleeding
- New leg swelling or calf pain
Prognosis
Mortality is high without treatment (approximately 30%). With appropriate anticoagulation, mortality drops to 2โ8%. Massive PE carries 25โ65% mortality even with treatment. Long-term, 2โ3% of patients develop chronic thromboembolic pulmonary hypertension (CTEPH). Recurrence risk is 5โ10% in the first year after treatment cessation; higher in unprovoked PE, malignancy, and thrombophilia.
Referral Criteria
ICU & EMERGENCY RESUSCITATION INDICATIONS
- Massive PE with haemodynamic collapse
- Post-cardiac arrest from PE
- Systemic thrombolysis administered (ICU monitoring required)
- Surgical embolectomy
- Severe RV failure requiring inotropic support
HOSPITAL ADMISSION INDICATIONS
- All high-risk (massive) PE
- Intermediate-high risk PE (elevated troponin + RV dysfunction)
- Haemodynamic instability or SpOโ <90%
- Inability to anticoagulate safely as outpatient
- Significant comorbidities
- Haematology: thrombophilia workup, antiphospholipid syndrome, recurrent VTE
- Pulmonology: persistent dyspnoea, suspected CTEPH
- Pulmonary hypertension centre: confirmed CTEPH
- Oncology: malignancy-associated PE
- Obstetrics: PE in pregnancy
All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.